WARRANT AGENCY AGREEMENTWarrant Agency Agreement • September 16th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of August __, 2021 (“Agreement”), between XORTX Therapeutics Inc., a British Columbia corporation (the “Company”), Continental Stock Transfer & Trust Company, a New York corporation (collectively as “Warrant Agent”).
PRE-FUNDED COMMON SHARE PURCHASE WARRANT XORTX Therapeutics, INC.XORTX Therapeutics Inc. • September 16th, 2021 • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from XORTX Therapeutics, Inc., a company organized under the laws of British Columbia (the “Company”), up to ______ common shares, no par value (the “Common Shares”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Form of Underwriter’s Warrant AgreementXORTX Therapeutics Inc. • September 16th, 2021 • Pharmaceutical preparations • New York
THIS PURCHASE WARRANT IS EXERCISABLE ON [________], 2021. VOID AFTER 5:00 P.M., EASTERN TIME, [________], 2026 [DATE THAT IS FIVE (5) YEARS FROM THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT].
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT is made as of the 1st day of August, 2021Employment Agreement • September 16th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Alberta
Allen Davidoff, an individual residing in the City of Calgary, in the Province of Alberta (hereinafter called the “EMPLOYEE”).
UNDERWRITING AGREEMENTUnderwriting Agreement • September 16th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
XORTX Therapeutics Inc., a company organized under the laws of British Columbia (the “Company”), proposes to issue and sell, severally and not jointly, to A.G.P./Alliance Global Partners (the “Representative”) and the other underwriters named on Schedule I hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) (i) an aggregate of [__] common share units (the “Common Share Units”), with each Common Share Unit consisting of (A) one common share (each a “Firm Share” and collectively the “Firm Shares”), no par value per share, of the Company (the “Shares”), and (B) a warrant to purchase [__] Shares (each a “Firm Warrant” and collectively the “Firm Warrants”) and (ii) an aggregate of [ ] pre-funded warrant units (the “Pre-Funded Warrant Units”), with each Pre-Funded Warrant Unit consisting of (A) a pre-funded warrant to purchase [__] Shares at an exercise
CONSULTING AGREEMENTConsulting Agreement • September 16th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Alberta
This Consulting Agreement (“Agreement”) is entered into as of March 1, 2018 (the “Effective Date”) between XORTX Therapeutics Inc., a Ontario incorporated company (“XORTX”) and W.B. Rowlands & Co.Ltd. (the “Consultant”).
